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A cDNA library from phorbol ester-induced human herpesvirus-8 (HHV-8) carrying BCBL-1 cells was screened with an
HIV1KS1 serum, and several cDNA clones encoding HHV-8 proteins were identified. Sequence analysis of two full-length
cDNA clones show open reading frames (ORFs) encoded by spliced messages originating from the HHV-8 K8.1 gene. One
cDNA encodes an ORF of 228 amino acids, designated K8.1.A, with a cleavable signal sequence, a transmembrane domain,
and four N-glycosylation sites. The splicing event generated the transmembrane domain in the ORF not seen in the genomic
K8.1 ORF. Another cDNA encodes an ORF of 167 amino acids, designated K8.1.B, that shares similar amino and carboxyl
termini with ORF K8.1.A but with an in-frame deletion. The primary translation products of ORF K8.1A (34 kDa) and K8.1B (20
kDa) in the in vitro–transcription–translation experiments shifted into glycosylated species of 43 and 32 kDa, respectively, in
the presence of microsomal membranes. This suggested that the ORF K8.1A and K8.1B encode for glycoproteins. Riboprobes
from the K8.1A cDNA insert hybridized with an HHV-8-specific 0.9-kb abundant transcript from BCBL-1 cells. Synthesis of this
RNA was eliminated in the presence of a DNA synthesis inhibitor, suggesting that this RNA was a late gene transcript.
Because ORFs K8.1A and K8.1B are unique for HHV-8, human sera were tested in Western blot reactions for antibodies
against glutathione-S-transferase–ORF K8.1A fusion protein. All sera that were positive for HHV-8 antibodies in immunoflu-
orescence assays with phorbol ester-induced BCBL-1 cells were also positive for anti-ORF K8.1A antibodies. This suggests
that measurement of anti-ORF K8.1A antibodies would provide an HHV-8-specific serological assay. Further work is needed
to define the biological role of the HHV-8 ORF K8.1A and K8.1B glycoproteins. © 1998 Academic Press
INTRODUCTION
Human herpesvirus-8 (HHV-8), or Kaposi’s sarcoma
(KS)-associated herpesvirus (KSHV), is a newly identified
lymphotropic herpesvirus with a strong association with
KS (Chang et al., 1994, 1995). HHV-8 DNA has been
detected in .95% of KS lesions studied, in both HIV2
and HIV1 individuals and in all clinical subtypes of KS
(Ambroziak et al., 1995; Chang et al., 1994, 1996; Moore
et al., 1995; Smith et al., 1997). In addition, HHV-8 se-
quences have been detected in body cavity-based B-cell
lymphomas (BCBLs). Cell lines (BC-1, HBL-6, and
BCBL-1) have been established from the BCBL tumors
(Cesarman et al., 1995; Gao et al., 1996, 1996; Moore et
al., 1996; Renne et al., 1996). BC-1 and HBL-6 carry both
HHV-8 and human Epstein–Barr virus (EBV). BCBL-1 cells
carry only HHV-8, and lytic cycles can be induced by
phorbol ester (TPA) (Chan et al., 1998; Chandran et al.,
1998; Renne et al., 1996; Smith et al., 1997). BCBL cells
have been used in immunofluorescence and Western
blot assays to measure antibody responses in human
sera (Chandran et al., 1998; Gao et al., 1996a, 1996b;
Kedes et al., 1996; Lennette et al., 1996; Smith et al.,
1997).
Sequence of ;140-kb HHV-8 DNA encoding 80 com-
plete ORFs was published very recently (Neipel et al.,
1997; Russo et al., 1996). Phylogenetic analysis of the
HHV-8 genome, the gene arrangements, and protein
sequences deduced from these sequences show strik-
ing similarity to herpesvirus Saimiri (HVS), a Simian her-
pesvirus, and more distantly related to EBV; both viruses
are in the g-herpesvirus group (Albrecht et al., 1992; Kieff
et al., 1996; Russo et al., 1996; Neipel et al., 1997). These
HHV-8 ORFs are currently identified as ORFs 1–75 by
their similarity to HVS ORFs. Russo et al. (1996) also
identified 15 ORFs unique for HHV-8 designated K1–K15.
Neipel et al. (1997) identified four additional HHV-8
unique ORFs and assigned decimal K numbers for them
(K4.1, K4.2, K8.1, and K10.1). Sera from HIV1KS1 and
HIV1KS2 individuals immunoprecipitated several HHV-
8-specific polypeptides and glycoproteins (Chandran et
al., 1998). Characterizations of HHV-8 proteins are fun-
damental to a rational understanding of the biology of
HHV-8 and its role in KS and other human diseases and
for diagnostic purposes. As an initial step, we screened
a cDNA library from TPA-induced BCBL-1 cells with an
HIV1KS1 serum and identified cDNAs encoding several
HHV-8 proteins (Chandran et al., 1998). Among these, we
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have identified two cDNAs encoded by the genomic
HHV-8 ORF K8.1. These two cDNAs are generated by
spliced transcripts and encode immunogenic glycopro-
teins.
RESULTS
Identification of cDNA encoding glycoproteins HHV-8
ORF K8.1A and K8.1B
To identify the genes encoding immunogenic HHV-8
proteins, serum from an HIV1KS1 individual with an
immunofluorescence assay (IFA) titer of 1:10,240 with
induced BCBL-1 cells was used to screen the cDNA
library from TPA-induced BCBL-1 cells. After four screen-
ings, 56 cDNA clones were isolated and released in the
phagemid forms by cocultivation with the helper phage.
These cDNAs were sequenced from both orientations.
Sequences were analyzed for ORF and compared with
the published genomic HHV-8 sequence (Russo et al.,
1996; Neipel et al., 1997). Several ORFs were identified
(Chandran et al., 1998). Complete HHV-8 ORF 65 was
encoded in 11 cDNA clones. In the other cDNA clones,
the length of ORFs ranged from 280 to 800 amino acids
(AA). Because these clones were identified by the
HIV1KS1 serum, this suggests that they encode immu-
nogenic protein regions.
Initial comparison of the nucleotide sequences of four
cDNA clones from the above screening showed 100%
identity to a 1200-bp region in the HHV-8 genomic se-
quence characterized by Russo et al. (1996) and Neipel
et al. (1997) (Fig. 1A). In this region, there is an ORF
designated K8.1, which starts at the genomic nucleotide
position 76,214 bp, ends at 76,808 bp, and thus encodes
a 197-AA-long ORF with a predicted molecular mass of
;22 kDa (Fig. 1A) (Neipel et al., 1997). The genomic K8.1
ORF has an amino-terminal signal sequence and five
putative N-glycosylation sites but no transmembrane se-
quence. Among the four cDNA clones identified, two
cDNA clones encoded two full-length ORFs of 228 and
167 AA (Figs. 1B, 1C, and 2). A comparison of these two
ORFs sequences with the genomic sequence showed
that they were encoded by spliced transcripts. The larger
cDNA is 752 bp long, starts at the genomic nucleotide
position 76,214 bp, ends at position 76,941 bp, and uses
the polyadenylation signal sequence (AATAAA) at posi-
tion 77,013 bp. This cDNA encodes a 228-AA-long ORF
FIG. 1. Schematic representation of the cDNAs encoding the HHV-8 ORF K8.1A and K8.1B. (Top line) Schematic representation of HHV-8 long unique
region (LUR). (A) schematic representation of HHV-8 ORFs. (B and C) Location of the cDNAs in the HHV-8 genome. (Numbers) Genomic nucleotide
positions of ORFs (Russo et al., 1996). (Arrows) Direction of transcription. The cDNAs encoding ORFs K8.1A and K8.1B of 228 and 167 AA, respectively,
are shown. The splice sites are shown by the inverted V, and AAAA represents the poly(A)1 tail. (D) Schematic hydropathic analysis of the deduced
ORF K8.1A protein sequence from the cDNA. (Peaks above the horizontal axis) Hydrophilicity. (Peaks below the horizontal axis) Hydrophobicity. (S)
Putative signal sequence. (N) Putative N-glycosylation sites (N-X-T/S). (TM) Predicted transmembrane AA sequences. (K8.1B.DEL) AA sequences
deleted in the ORF K8.1B by splicing.
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with a predicted molecular mass of ;25 kDa and is
designated K8.1.A. The first 142 AA encoded by the K8.1A
cDNA are identical to the genomic K8.1 ORF sequence.
Analysis suggested that the protein encoded by the
K8.1A cDNA is a typical class I glycoprotein with a cleav-
able amino-terminal signal sequence or sequences, a
transmembrane domain (197–213 AA), seven cysteine
residues, and four putative N-glycosylation sites (N)
(Figs. 1B, 1D, and 2). This cDNA is derived from a tran-
script with a 95-bp sequence spliced out [CAG/(GT)GTAT
donor site and TCTAC(AG)/G acceptor site] and ends at
the genomic nucleotide position 76,941 bp, which is 187
bp beyond the end of genomic ORF K8.1 (Fig. 1B). This
has resulted in the generation of a transmembrane do-
main not seen in the genomic ORF K8.1.
The smaller cDNA is 569 bp long with a 183-bp se-
quence spliced out. The splice acceptor site for the ORF
K8.1B transcript is the same as that for the ORF K8.1A
transcript (Figs. 1C and 2). However, the splice donor site
[CGA/(GT)GAGT] for the K8.1B cDNA is upstream of the
splice donor site of the K8.1.A cDNA, resulting in an
in-frame deletion of 61 AA in the smaller ORF (Figs. 1D
and 2). The resulting 167-AA-long ORF is predicted to
code for a protein of ;18.5 kDa and is designated K8.1.B.
ORF K8.1B is also a typical class I glycoprotein with a
cleavable signal sequence, a transmembrane domain,
and three putative N-glycosylation sites (N). Except one
AA change near the splice site (S to R), the ORF K8.1B
shares identical AA sequences with ORF K8.1.A (Figs. 1C
and 2). To confirm the sequence and the splicing pat-
terns, 59-rapid amplification of cDNA ends (RACE) was
done. RNA extracted from TPA-induced BCBL-1 cells (48
h p.i.) was used for this. Single-stranded cDNAs from
TPA-induced cells were synthesized using oligo(dT)
primer, and the second strand was subsequently synthe-
sized. Double-stranded adapters were ligated to both
ends of the cDNA molecule, and polymerase chain re-
action (PCR) was performed using an adapter-specific
FIG. 2. Sequence analysis of the HHV-8 ORF K8.1A and K8.1B cDNA. Nucleotide and the predicted AA sequence of the full-length cDNA encoding
ORF K8.1A and K8.1B are shown. The AA position is numbered on the right. The ORF termination codon (TAA), the putative polyadenylation signal
sequence (ATTAAA), and putative N-glycosylation sites (N-X-T/S) are underlined and in bold. (1) Predicted transmembrane (TM) AA sequence. (Dotted
lines) AA sequences of ORF K8.1B shared with ORF K8.1A. (p) Splice site in ORF K8.1B.
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primer and the ORF K8.1A- and K8.1B-specific primer
corresponding to the 39-end stop site. Several clones
were cloned and sequenced. The sequences and splic-
ing patterns were identical to those of the ORF K8.1A and
K8.1B cDNAs, confirming the sequences and the splicing
pattens seen in the K8.1A and K8.1B cDNAs.
The proteins encoded by cDNAs HHV-8 ORFs K8.1A
and K8.1B are glycoproteins
By AA sequence analysis, the ORFs K8.1A and K8.1B
identified here are predicted to encode for glycoproteins.
To verify this, in vitro transcription-translation experi-
ments were done. No specific protein was detected in
control reactions without the addition of any RNA (Fig. 3,
lane 1). Translation of the RNA transcribed from K8.1B
cDNA produced a polypeptide of ;20 kDa (Fig. 3, lane 2).
With the addition of canine microsomal membranes to
the translation reaction mixture, this polypeptide shifted
in mobility to a polypeptide of ;32 kDa (Fig. 3, lane 3).
The major primary translation product of K8.1.A cDNA is
a 34-kDa polypeptide (Fig. 3, lane 4), and in the presence
of microsomal membranes, it shifted into a glycosylated
species of 43 kDa (Fig. 3, lane 5). Treatment of these in
vitro synthesized products in the presence of mem-
branes with N-glyconase decreased the 43- and 32-kDa
polypeptides into smaller polypeptides of ;34 and ;20
kDa (data not shown), indicating the removal of N-linked
oligosaccharides. These results showed that the HHV-8
ORF K8.1A and K8.1B cDNAs encode glycoproteins.
HHV-8 ORF K8.1A and K8.1B cDNAs are generated
from a late class transcript
To define further the viral specificity of the HHV-8 ORF
K8.1A and K8.1B cDNA inserts, RNA was isolated from
uninduced and TPA-induced BCBL-1 and BJAB cells. To-
tal RNAs were analyzed by Northern blot hybridization
with a 0.7-kb antisense RNA probe transcribed from the
HHV-8 ORF K8.1A cDNA insert. No hybridization was
detected with total RNAs from uninduced and TPA-in-
duced BJAB (HHV-82) cells (Fig. 4A, lanes 1 and 2).
Under the conditions of high stringency, the K8.1A RNA
probe hybridized specifically to a prominent band of
;0.9 kb and a less prominent band of ;0.7 kb from
uninduced and TPA-induced cells (48 h p.i.) (Fig. 4A,
lanes 3 and 4). Longer exposure of the autoradiograph
was required to detect the hybridization with uninduced
BCBL cell RNA. Longer exposure also revealed several
additional RNAs from uninduced and TPA-induced
BCBL-1 cells (Figs. 4A, lanes 3 and 4, and 4B, lanes 3–7),
FIG. 4. (A, Top) Identification of transcripts hybridized with the ribo-
probe from the ORF K8.1A cDNA insert. Total unfractionated RNA was
isolated from uninduced and TPA-induced BJAB (lanes 1 and 2) and
from uninduced and TPA-induced BCBL-1 cells (lanes 3 and 4). Sam-
ples were analyzed by Northern blot hybridization with a radiolabeled,
in vitro transcribed RNA probe synthesized from the 0.7-kb ORF K8.1A
cDNA insert. (A, Bottom) Membrane from A was stripped and probed
with a radiolabeled GAPDH RNA probe. The sizes (in kb) of the hybrid-
ized RNAs are indicated. Standard RNA marker molecules of known
sizes were included in parallel lanes. (B) Kinetics of RNAs identified by
HHV-8 ORF K8.1A insert. (Top) Total unfractionated RNA was isolated
from cells. (Lane 1) Uninduced BJAB. (Lane 2) TPA-induced BJAB cells.
(Lane 3) Uninduced BCBL-1 cells. (Lane 4) BCBL-1 cells collected after
24 h of TPA induction. (Lane 5) BCBL-1 cells collected after 24 h of PAA
and TPA treatment. (Lane 6) BCBL-1 cells collected after 48 h of TPA
induction. (Lane 7) BCBL-1 cells collected after 72 h of TPA induction.
This autoradiograph was exposed longer than the one shown in Figure
4A. (Middle) Membrane from B was stripped and probed with a radio-
labeled GAPDH RNA probe. (Bottom) Membrane from the middle was
stripped and probed with a riboprobe synthesized from an HHV-8 cDNA
encoding the early-late HHV-8 ORF 59 protein (Chan et al., 1998).
FIG. 3. In vitro translation of RNAs transcribed from the cDNA inserts
encoding HHV-8 ORF K8.1A and K8.1B. Antisense transcripts prepared
in vitro from the cDNA insert were translated in vitro using rabbit
reticulocyte lysates and [35S]methionine. (Lane 1) Translation without
the addition of RNA. (Lane 2) Translation of K8.1B RNA transcribed from
SP6 promoter in the absence of microsomal membranes. (Lane 3)
Translation of K8.1B RNA in the presence of microsomal membranes.
(Lane 4) Translation of K8.1A RNA transcribed from SP6 promoter in the
absence of microsomal membranes. (Lane 5) Translation of K8.1A RNA
in the presence of microsomal membranes. (Numbers) Approximate
molecular mass (in kDa) of the major in vitro translated polypeptides
and the glycosylated species. Samples were analyzed on 12% acryl-
amide cross-linked with N,N9-diallyltartardiamide.
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with the 0.9-kb species being the most abundant (Figs.
4A and 4B). The calculated sizes of the other faint RNA
bands detected were 1.4 and 0.5 kb (Figs. 4A and 4B).
Because the 0.9-kb transcript was similar in size to the
cDNA clones of ORF K8.1A and K8.1B, we concluded that
this transcript must arise from the K8.1 gene. To confirm
that an equal amount of RNA was loaded in each sample
and to verify the integrity of the RNA samples, the
membrane was stripped and then rehybridized with the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
probe, a cellular constitutive enzyme expressed in all
cells. No appreciable difference in the intensity of
GAPDH RNA was observed in samples from uninduced
and TPA-induced BCBL-1 and BJAB cells (Fig. 4A).
To determine the kinetics of the transcript identified by
HHV-8 ORF K8.1A insert, RNA extracted from TPA-in-
duced cells collected at 24, 48, and 72 h p.i. was hybrid-
ized with the antisense RNA probe transcribed from the
K8.1A cDNA insert (Fig. 4B). This autoradiograph was
exposed for a longer time than the autoradiograph
shown in Figure 4A. No hybridization was detected with
total RNA from uninduced and TPA-induced BJAB (HHV-
82) cells (Fig. 4B, lanes 1 and 2). All the different RNA
species hybridized with the K8.1A probe could be de-
tected in both uninduced and TPA-induced cells (24 h
p.i.) (Fig. 4B, lanes 3 and 4). The highest level of the
0.9-kb message was detected at 48 h p.i. (Fig. 4B, lane 6)
and reduced by 72 h p.i. (Fig. 4B, lane 7). In contrast, the
synthesis of the 1.4-kb band decreased appreciably by
48 h and was barely detectable by 72 h. This indicated
differential regulation of the transcripts from the HHV-8
ORF K8.1A gene locus.
To determine whether the HHV-8 ORF K8.1A RNA tran-
script belongs to the early or late class of transcripts
expressed in lytic infection, TPA-induced BCBL-1 cells
were incubated with PAA for 24 h. At 24 h p.i., the 0.9-kb
transcript was not detectable in the TPA-induced, PAA-
treated cells (Fig. 4B, lane 5). In contrast, the 1.4-kb
transcript was detected in the presence of PAA but in a
lower amount than the untreated control (Fig. 4B, lanes 4
and 5). When this membrane was stripped and rehybrid-
ized with the GAPDH riboprobe, no inhibition of the
GAPDH RNA by PAA was observed. In contrast, the RNA
transcripts detected by a riboprobe synthesized from a
cDNA encoding the early-late class HHV-8 protein P50-
ORF59 (Chan et al., 1998) was not completely inhibited
by the PAA treatment (Fig. 4B, bottom). The complete
inhibition of the major 0.9-kb transcript by PAA sug-
gested that this transcript encoded by the HHV-8 gene
locus K8.1 should be classified as truly late transcript
(g-2). The 1.4-kb RNA resembles an early class of RNA.
The origin of this transcript is not known at present and
may arise from the adjacent ORF K8 or ORF 50 genes
encoding larger proteins. Similarly, the origin of the 0.7-
and 0.5-kb RNAs is not known at present. The polyade-
nylation signal sequence used by the K8.1A and K8.1B
transcripts also can be used by other preceding genes,
such as ORF K8 and ORF 50, with different splice pat-
terns with the 59 part of the K8.1A and K8.1B ORF without
including the 39 end of the K8.1A and K8.1B sequences.
Hence, K8.1A riboprobe still could recognize, albeit
weekly, other transcripts such as the 1.4-, 0.7-, and 0.5-kb
transcripts. The RACE techniques used here rely on the
amplification using the primer corresponding to the 39
stop site of K8.1A and K8.1B, and hence we specifically
amplified only the clones with the intact 39 end and not
the clones with sequences corresponding to the K8.1A
and K8.1B 39 part spliced out.
Expression of ORF K8.1A and K8.1B as a glutathione-
S-transferase (GST) fusion protein
HHV-8 ORFs K8.1A and K8.1B were subcloned into
GST-expression vectors and induced to express the fu-
sion proteins. The expected sizes of ORF K8.1A and K8.1B
fusion proteins were 52–54 and 42–44 kDa, respectively.
To verify their expression in bacteria, whole bacterial cell
extracts were tested in Western blot reaction with rabbit
anti-ORF K8.1A peptide antibodies and human sera. The
rabbit antibodies, designated Ra8.1A-NP and Ra8.1A-CP,
were raised against synthetic peptides corresponding to
ORF K8.1A AA residues 93–111 and 140–156, respectively
(Fig. 2). Because residues 93–111 are not present in the
ORF K8.1B protein due to splicing, antibodies against this
peptide were not expected to react with ORF K8.1B.
However, residues 140–156 are common to both ORFs,
and hence the Ra8.1A-CP antibodies were expected to
recognize both ORFs. No specific reactivity was seen
with the preimmune serum (Fig. 5A, lanes 1–3). As ex-
pected, the purified Ra8.1A-NP rabbit IgG antibodies re-
acted strongly with the 52–54-kDa GST-K8.1A fusion pro-
tein (Fig. 5B, lane 3) but not with the K8.1B fusion protein
(Fig. 5B, lane 2) or GST alone (Fig. 5B, lane 1). In contrast,
purified Ra 8.1A-CP rabbit IgG antibodies reacted
strongly with both K8.1A and K8.1B fusion proteins (Fig.
5C, lanes 2 and 3) but not with the GST protein (Fig. 5C,
lane 1). The reactivities of rabbit sera further verified the
AA sequences of the cDNA clones encoding K8.1A and
K8.1B and their expression in the GST system.
Reactivities of human sera with ORF8.1A expressed in
GST-expression system
Reactivities of human sera were next tested with the
unpurified GST K8.1A and K8.1B fusion proteins (Figs.
5D–5F). No specific reactivity was seen when the blots
were tested only with the alkaline phosphatase-labeled
anti-human antibodies (Fig. 5D, lanes 1–3). In contrast,
sera from HIV1KS1 and HIV1KS2 individuals recog-
nized the K8.1A and K8.1B fusion proteins but not the GST
protein (Figs. 5E and 5F). Although these reactivities
were specific, this method was not used further to test
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human sera due to the presence of other bacterial pro-
teins in these whole-cell extracts.
The GST-ORF K8.1A fusion protein and the GST alone
were further purified by passing through the Glutothione
Sepharose 4B, and the purity was verified by Coomassie
Blue stain of the gel (Fig. 6A) and by the reactivities of
purified Ra 8.1A-NP rabbit antibodies (Fig. 6B). Approxi-
mately equal quantities of these proteins (100 ng/10 ml)
were loaded per lane. The purified GST protein was
always localized below the 29-kDa marker (Fig. 6A, lane
1). The GST-ORF K8.1A protein was ;52–54 kDa, and the
additional lower-molecular-weight proteins detected
probably represent proteolytic products (Fig. 6A, lane 2).
A high-molecular-weight protein of ;72 kDa also was
detected and could represent a dimeric aggregate of
GST-ORF K8.1A protein (Fig. 6A, lane 2). The rabbit anti-
peptide antibodies (K8.1A-NP) recognized the 52–54-kDa
GST-ORF K8.1A protein and the high-molecular-weight
protein in Western blot reactions but not the GST protein
(Fig. 6B, lanes 1 and 2). To test the reactivities of sera
with the GST and GST-ORF K8.1A proteins, we used a
panel of sera that were previously tested for HHV-8
antibodies by IFA with TPA-induced BCBL-1 (HHV-81)
cells, with TPA-induced BJAB cells, and with TPA-induced
EBV producer cells P3HR-1 (Chandran et al., 1998). Spe-
cific bright cytoplasmic fluorescence with ;30% of TPA-
induced BCBL-1 cells were considered as recognizing
lytic HHV-8 antigens. Although sera were tested with a
starting dilution of 1:10, several sera showed nonspecific
fluorescence at 1:10 and 1: 20 dilutions with BCBL-1 and
BJAB cell. Hence, sera showing a reactivity at a dilution
of $1:40 were considered positive. These sera were
tested at a dilution of 1:40 with the GST and GST-ORF
K8.1A proteins by Western blotting, and positive sera
were retested by titration.
The sera were coded and tested in the Western blot
reactions in a blind manner. Several sera showed very
specific reactivities with the ORF-K8.1A protein but not
with the GST proteins (representative examples are
shown in Figs. 6C and 6D). Sera from 62 HIV1KS1
patients were tested, and 60 (97%) of them showed
specific reactivities with ORF K8.1A fusion protein (Table
1). The titer of these sera in these Western blot reactions
ranged from 1:160 to 1:10,240 (an example is shown in
Fig. 6C, lanes 1–6). All the sera that tested positive by
Western blotting were also positive for HHV-8 antibodies
by IFA with TPA-induced BCBL-1 cells (Table 1). Among
the 38 sera from HIV1KS2 patients tested, 23 (61%)
showed reactivities with the GST-ORF K8.1A fusion pro-
tein, and the titer of these sera ranged from 1:40 to
1:2560. Initial testing of HIV1KS2 sera at a dilution of
1:40 dilution of sera showed varying degrees of GST-ORF
K8.1A band intensity (Fig. 6D, lanes 1–6). This probably
reflected the titer of these sera. All the HIV1KS2 sera
FIG. 6. Reactivities of human sera with column purified GST-ORF
8.1A. (A) GST and GST-ORF K8.1A fusion protein were purified by
passing through the Glutathione Sepharose 4B, and the purity was
verified by Coomassie Blue stain of the gel. Samples were analyzed on
12% acrylamide cross-linked with DATD. (Numbers) Approximate mo-
lecular mass (in kDa). (Lane 1) Column-purified GST. (Lane 2) Column-
purified GST-ORF K8.1.A. (Lane 3) Molecular weight markers. (Arrows)
Location of GST and the GST-ORF K8.1A fusion protein. (B–E) Reactiv-
ities of sera in Western blot reactions. (Lanes 1, 3, and 5) Column-
purified GST. (Lanes 2, 4, and 6) Column-purified GST-ORF K8.1.A. (B)
Reactivities of rabbit anti-K8.1A-CP peptide antibodies (1:500 dilution).
(C) Reactivities of an HIV1KS1 serum at a dilution of 1:640 (lanes 1
and 2), 1:1280 (lanes 3 and 4), and 1:2560 (lanes 5 and 6). (D and E)
Reactivity of HIV1KS2 sera at a dilution of 1:40. (Arrow) Location of
GST-ORF K8.1A fusion protein.
FIG. 5. Western blot reactions with total bacterial cell extracts con-
taining GST and GST-ORFs 8.1A and 8.1B. (Lanes 1–3) Total bacterial
cell extracts expressing GST only, GST-ORF K8.1B, and GST-ORF K8.1A,
respectively. All rabbit sera were tested at 1:500 dilution. (A) Reactivi-
ties of the preimmune rabbit serum. (B) Reactivities of rabbit anti-
K8.1A-NP antibodies raised against synthetic peptide (AA 93–111) cor-
responding to the amino terminus of ORF K8.1A not present in ORF
K8.1B. (C) Reactivities of rabbit anti-K8.1A-CP antibodies raised against
synthetic peptide (AA 140–156) corresponding to the carboxyl termini of
ORFs K8.1A and K8.1B. (D) Reactivities of alkaline phosphatase-labeled
anti-human antibodies. (E) Reactivities of a serum (1:640 dilution) from
HIV1KS2 individual. (F) Reactivities of a serum (1:640 dilution) from
HIV1KS1 individual. The locations of GST, ORF 8.1A, and ORF 8.1B are
indicated.
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that were positive by Western blotting were also positive
for HHV-8 lytic antibodies by IFA (Table 1).
Sera from HIV1KS2 patients that were negative for
HHV-8 antibodies by IFA were also negative when tested
with the ORF K8.1A protein (Fig. 6E, lanes 1–6). Similarly,
sera from 48 children (ages 1–5) were negative both in
IFA and in Western blots (Table 1). We also tested 120
sera from age-matched (18–50 years) HIV2 healthy adult
men, and among these, 45 were from blood bank donors
and 75 were from adult men from the general population.
The sexual orientation of these individuals is not known.
Only 9 (8%) of the 120 HIV2 men were positive for HHV-8
lytic antibodies by IFA. All 9 sera were also positive in
Western blot reactions, and their antibody titers ranged
from 1:40 to 1:160. (Table 1). Three (3 of 45, or 6.6%) of
these positive sera were from blood bank donors, and six
(6 of 75, or 8%) were from the other adult male groups.
These results suggested that testing the antibodies
against ORF K8.1A protein provide a specific HHV-8 se-
rological assay.
DISCUSSION
Our earlier studies showed that human humoral re-
sponses were directed against a number of HHV-8 pro-
teins (Chandran et al., 1998). Sera from HIV2KS2 indi-
viduals and from a majority of HIV1KS2 individuals had
low titers of HHV-8 antibodies, recognizing only a subset
of viral proteins (Chandran et al., 1998). Hence, it is
critical to use immunogenic antigens detecting the low
level of antibodies, presumably the persisting antibody
responses, to study the HHV-8 seroprevalence. HHV-8
ORF 73 is identified as being responsible for the majority
of the LANA-type reactivities of sera (Rainbow et al.,
1997). Simpson et al., (1996) and Lin et al., (1996) identi-
fied the HHV-8 ORF65 protein as an immunogenic lytic
cycle associated protein. However, not all HIV1KS1
sera showed positive reactions with the ORF 65 protein,
suggesting that a more immunodominant antigen needs
to be used. The initial identification of cDNA encoding
the HHV-8 ORF K8.1A and K8.1B by screening the cDNA
library with an HIV1KS1 serum suggested that these
proteins encoded immunogenic domains. We selected
the ORF K8.1A for further testing with sera because it
possesses AA not present in ORF K8.1B. Our results
showed a high degree of concordance between IFA
detecting HHV-8 lytic antibody responses and Western
blot reactions detecting anti-ORF K8.1A antibodies. All
sera that were seropositive by IFA with TPA-induced
BCBL-1 cells were also positive for anti-ORF K8.1A anti-
bodies. Although the IFA using TPA-induced BCBL-1
cells is specific for HHV-8 and detects a spectrum of
responses against the various HHV-8 antigens, it is te-
dious, subjective, and hampered by nonspecific reac-
tions at lower dilutions of sera. The ORF K8.1A is specific
for HHV-8, suggesting that this protein can be used to
develop a sensitive and specific assay to measure
HHV-8 seroprevalence in the population. We have cloned
and expressed the ORF K8.1A and K8.1B, ORF 73, and
ORF 65 in baculovirus system, and attempts are on the
way to develop a rapid comparative ELISA measuring
lytic and latent antibodies.
Our results showed that the HHV-8 ORF K8.1 gene
encodes glycoproteins generated from spliced tran-
scripts. The Northern blot hybridization kinetic experi-
ments suggested that these transcripts belong to the
truly late class transcript. Analysis of HHV-8 genomic
sequences show that like other herpes viruses, HHV-8
encodes for several glycoproteins. We have shown that
HHV-8-specific glycoproteins are good targets for human
humoral immune responses (Chandran et al., 1998).
From BCBL-1 cells, HHV-8 antibody-positive human sera
recognized several glycoproteins with an approximate
molecular weights of 128,000, 116,000, 105,000, 80,000,
75,000, 65,000, 60,000–55,000, 50,000, 45,000, 41,000–
38,000, and 34,000–32,000. These glycoproteins are
probably encoded by the HHV-8 ORF K1, 8, 22, 47, and
K8.1 genes (Neipel et al., 1997; Russo et al., 1996). The
identity of the individual glycoproteins encoded by these
genes, including the ORF K8.1A and K8.1B, must be
determined. Preliminary studies with anti-ORF K8.1A and
K8.1B antibodies show that ORF 8.1A and 8.1B glycopro-
teins are present in the HHV-8 virion envelopes, and the
broader glycoproteins in the 45,000–38,000 regions rec-
ognized by human sera (Chandran et al., 1998) are en-
coded by the HHV-8 ORF K8.1A and K8.1B (data not
shown). Further characterization of these glycoproteins
will be presented elsewhere.
Among the different glycoproteins encoded by HHV-8,
ORFs 8, 22, and 47 are homologous to the glycoproteins
gB, gH, and gL, respectively, which are conserved
among the other herpes viruses. In contrast, compari-
sons with the human or animal herpes viruses se-
quences to date show that the ORFs K8.1A and K8.1B are
unique for HHV-8. This suggests that ORF K8.1A and
TABLE 1
Reactivities of Human Sera with HHV-8 ORF K8.1A
Sera from
Number
tested
Number 1 (%)
ORF K8.1A WBa BCBL-IFAb
HIV1KS1 patients (USA) 62 60/62 (97%) 60/62 (97%)
HIV1KS2 gay men (USA) 38 23/38 (61%) 23/38 (61%)
Healthy adult men (HIV2)
(USA)
120 9/120 (8%) 9/120 (8%)
Children (1–5 yr) (USA) 48 0/48 0/48
a Sera were tested at a starting dilution of 1:40 with Western blotted
GST and GST-ORF K8.1A protein.
b Sera were tested at a starting dilution of 1:10 with TPA-induced
HHV-81 BCBL-1 cells and TPA-induced HHV-82 BJAB cells (Chandran
et al., 1998).
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K8.1B glycoproteins may be mediating important biolog-
ical function or functions specific for HHV-8. The location
of the HHV-8 ORF K8.1A gene in the genome strengthens
such a notion. The HHV-8 K8.1A gene is positionally
colinear to the EBV gene encoding the major EBV glyco-
proteins gp350/gp220 (Kieff et al., 1996; Neipel et al.,
1997). Similar to HHV-8 ORF K8.1B, the EBV gp220 arises
from an in-frame deletion of gp350 gene (Kieff et al.,
1996). The gp350 and gp220 are highly glycosylated with
several N- and O-linked sugar attachments (Kieff et al.,
1996). In addition to the potential N-glycosylation sites,
the HHV-8 ORFs K8.1A and K8.1B possess a high number
of serine and threonine residues (28 and 20, respective-
ly), which are the potential sites for O-glycosylation.
Studies are in progress to determine the nature of sugars
in the ORF K8.1A and K8.1B. The EBV gp350 and gp220
are responsible for the specific B-cell tropism of the virus
in that they are the first viral contact protein mediating
the binding to the receptor for complement fragment C3d
(Kieff et al., 1996). HHV-8 also infects B-cells (Boshoff et
al., 1995; Rennne et al., 1996), and it is not clear whether
it uses the same receptor as EBV. Because HHV-8 DNA
and transcripts were shown to be present in macro-
phages (Orenstein et al., 1997) and endothelial cells
(Staskus et al., 1997), HHV-8 may have broader tropism
than EBV. Further studies are in progress to define the
HHV-8 ORF 8.1A and 8.1B glycoproteins in the virions; the
role of these two different proteins in HHV-8 biology,
such as binding and entry into cells; and the ability of
anti-K8.1A and -K8.1B antibodies to neutralize the infec-
tivity.
MATERIALS AND METHODS
Cell lines
HHV-81 and EBV2 body cavity B-cell lymphoma cell
line BCBL-1 (a gift from Dr. McGrath, University of Cali-
fornia at Los Angeles) (Renne et al., 1996) was grown in
RPMI 1640 medium with glutaMAX I (GIBCO BRL, Grand
Island, New York) supplemented with 10% heat-inacti-
vated fetal bovine serum and antibiotics.
Serum samples and IFA
Sera from HIV1KS1 and HIV1KS2 homosexual adult
male patients (ages 18–50), age-matched HIV2KS2
adult men, and children (ages 1–5) were used in these
studies (Chandran et al., 1998; Smith et al., 1997). All sera
were stored at 220°C and heat inactivated at 56°C for
30 min before use. IFA with TPA-induced BCBL-1 cells
was performed as described previously (Chandran et al.,
1998; Smith et al., 1997).
Construction of cDNA library and screening of ZAPII
expression system
BCBL-1 cells were induced with 20 ng/ml TPA (Sigma
Chemical Co., St. Louis, Missouri), and aliquots were
collected at 24, 48, 72, and 96 h postinduction. For re-
verse transcription (RT)–PCR, total RNA was extracted
from these cells, treated with RQ1-DNase (Promega,
Madison, Wisconsin), and verified for the absence of
HHV-8 DNA by DNA-PCR using ORF 25 and 26 primers
(Smith et al., 1997). The mRNA was isolated by Oligotex
mRNA isolation kit (Qiagen, Chatsworth, California) and
used in cDNA synthesis using oligo(dT) linker-primer
containing XhoI site (Stratagene, La Jolla, California) ac-
cording to the manufacturer’s recommendations. Synthe-
sized cDNAs were tested for HHV-8 messages by DNA-
PCR using HHV-8 ORFs 22, 25, and 26 primers as
described previously (Smith et al., 1997), and appropri-
ate-size fragments were detected. The cDNA library in
the ZAPII expression system was made according to the
manufacturer’s recommendations. After amplification,
this library had a titer of ;4 3 109 pfu/ml with 99%
recombinant phages.
More than 100,000 plaques from this library were
screened with an HIV1KS1 serum (IFA titer, 1:10,240)
using procedures described previously (Chang and Bala-
chandran, 1991). To remove nonspecific reactivities, the
serum was absorbed with HHV-82 control B-cells (BJAB)
and with bacterial lysates containing nonrecombinant
phages. The absorbed serum was diluted 1:6000 in the
blocking buffer (Chang and Balachandran, 1991) and
used to screen the library. Immunoreactive phages were
picked and purified by four subsequent steps of screen-
ing. After four screenings, 56 clones were isolated. The
identified cDNAs were released into the phagemid forms
by in vivo excision using the ExAssist helper phage.
59 RACE
The sequences of the isolated K8.1A and K8.1B cDNA
clones and the splicing events were verified by 59 RACE.
This was done by using the Marathon cDNA amplifica-
tion kit (Clontech, Palo Alto, California) and the RNA
extracted from TPA-induced BCBL-1 cells (48 h postin-
duction). Single-stranded cDNAs were synthesized using
Moloney murine leukemia virus–RT and an oligo(dT)
primer provided with the kit. The second strand was
synthesized, and double-stranded adapters were ligated
to both ends of the cDNA molecules. These cDNAs were
amplified by PCR using an adapter-specific primer pro-
vided in the kit and with an HHV-8-specific primer cor-
responding to the ORF K8.1A and K8.1B 39-end stop site
(59-ATGGTTTTGTGTTACACTATGTAGGG-39). These dou-
ble-stranded cDNA PCR products were ligated into the
PGEM-T vector.
DNA sequence analysis
The cDNA clones (both orientations) were sequenced
in the Biotechnology Center at the University of Kansas
Medical Center. Sequences were analyzed and com-
pared with the data bank by BLAST program. The two
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ORFs encoded by the cDNAs were designated as HHV-8
ORF K8.1A and K8.1B.
Raising rabbit antibodies against synthetic peptides
recognizing HHV-8 ORF K8.1A and K8.1B
To raise anti-peptide antibodies, two peptide regions
in the HHV-8 ORF K8.1A AA sequences were selected
based on the hydropathic (Kyte–Doolittle method), anti-
genic (Jameson–Wolf method), and surface probability
(Emini method) profiles. The peptide designated
K8.1A-NP (TSASGSGEDAIDESGSGEE- AA 93–111) corre-
sponds to the amino terminus of the HHV-8 ORF K8.1A.
This stretch of AA is not present in the ORF K8.1B due to
a splicing event resulting in an in-frame deletion. The
peptide designated K8.1A-CP (FSGSYSSGEPSRTTRIR-
AA 140–156) corresponds to the carboxyl terminus of
HHV-8 ORFs K8.1A and K8.1B and is absent in the
genomic HHV-8 ORF K8.1. These two peptides were syn-
thesized over a core of poly-L-lysine in the Biotechnology
Center. New Zealand White male rabbits were first im-
munized subcutaneously and intramuscularly with 100
mg of peptides in Freund’s complete adjuvant. Twenty
and 40 days later, rabbits were immunized with the same
amount of antigens in Freund’s incomplete adjuvant. The
rabbits were boosted 2 months after the last injection
and were bled 10 days later. IgG antibodies (Ra 8.1A-NP
and Ra8.1A-CP) were purified from the sera by affinity
chromatography on a Protein A–agarose column.
Construction and expression of HHV-8 ORF K8.1A and
K8.1B in the GST gene fusion system
HHV-8 ORFs K8.1A and K8.1B from the cDNAs were
amplified using 59 primer (cggggatccatgagttccacacagat-
tcgc with a BamHI site) and 39 primer (atggtctcgagtta-
cactatgtagggtttc with an XhoI site). Amplified PCR frag-
ments were purified and ligated into pGEM-T vector
(Promega). Orientation was verified by restriction en-
zyme digestion and sequence analysis. These plasmids
were digested with BamHI and XhoI and inserted into the
GST expression vector pGEX-4T-1 (Pharmacia, Piscat-
away, New Jersey). Orientation was verified by restriction
enzyme digestion. Induction of fusion protein was done
by adding IPTG (1 mM) to bacterial cultures grown to an
OD600 of 0.2–0.5. The induced GST and GST-ORF K8.1A
fusion proteins were purified by Glutathione Sepharose
4B (Pharmacia) according to the manufacturer’s recom-
mendations.
In vitro transcription and in vitro translation of cDNA
In vitro transcription of the HHV-8 ORF K8.1A and K8.1B
cDNA inserts in pGEM-T was done by linearizing the
plasmid with appropriate restriction enzymes and syn-
thesizing sense RNA transcripts using Sp6 polymerase.
Capping of RNA at 59 was carried out according to
procedures described in the Riboprobe transcription sys-
tem instruction manual (Promega). RNA samples from in
vitro transcription experiments were translated in vitro
using [35S]methionine and rabbit reticulocyte lysate
preparations (Promega) with and without microsomal
membranes according to the manufacturer’s recommen-
dations. In vitro translated products were boiled in sam-
ple buffer, and equal trichloroacetic precipitable counts
were analyzed by SDS–PAGE. The in vitro synthesized
products in the presence of membranes were treated
with N-glyconase according to the procedures of Bala-
chandran and Hutt-Fletcher (1995).
Western blot reactions
Approximately 100 ng of each protein in a 10-ml vol-
ume was loaded per lane in the SDS–PAGE minigel
apparatus (BioRad, Hercules, California). Protein sam-
ples were separated in 12% acrylamide cross-linked with
DATD and electrophoretically transferred to nitrocellu-
lose sheets (Chang and Balachandran, 1991). Standard
molecular weight markers (Sigma) were included in par-
allel lanes. After the transfer, the membranes were
stained with Ponceau-S for 5 min, and the positions of
the transferred proteins and molecular weight markers
were marked. The stain was washed by distilled water.
The nitrocellulose membranes were subsequently incu-
bated overnight with blocking buffer (10 mM Tris–HCl, pH
7.2, 0.15 M NaCl, and 5% skim milk) and then reacted with
2–4 ml of blocking buffer containing appropriate dilutions
of rabbit antisera or human sera for 3 h at room temper-
ature. The membranes were washed with washing buffer
(10 mM Tris–HCl, pH 7.2, 0.15 M NaCl, and 0.3% Tween
20), and finally incubated for 1 h with alkaline phos-
phatase-conjugated goat anti-rabbit IgG or anti-human
IgG antibodies (HyClone Laboratories). After washing,
the bound antibodies were detected using 5-bromo-4-
chloro-3-indolylphosphate and nitroblue tetrazolium sub-
strate (Sigma).
RNA extraction, riboprobe synthesis, and Northern
blot hybridization
Total RNA was isolated from uninduced and TPA-in-
duced BCBL-1 cells and BJAB cells with and without PAA
treatment as described previously (Chan et al., 1998). The
RNA samples were analyzed by Northern blot hybridization
with antisense RNA probes transcribed from the HHV-8
ORF K8.1A and 59 cDNA (Chan et al., 1998) using the
Riboprobe kit (Promega). Northern blots were performed on
nylon membranes using standard methodology with 10 mg
of total RNA for each lane. Blotted membranes were hy-
bridized overnight at 65°C in 5 ml of RNA hybridization
buffer (53 Denhardt’s reagent, 53 SSPE, 0.5% SDS, 50%
formamide, and 100 mg/ml salmon sperm DNA) containing
;1 3 107 cpm of radiolabeled in vitro transcribed RNA.
After hybridization, membranes were washed as per stan-
dard procedures and exposed to Kodak XAR5 film at
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270°C. The membranes were stripped and then rehybrid-
ized with a GAPDH riboprobe and a riboprobe from a cDNA
(HHV-8 ORF 59) encoding HHV-8 early-late protein P50
(Chan et al., 1998).
Nucleotide sequence accession numbers
The nucleotide sequences reported here have been
deposited in the GenBank database and assigned ac-
cession numbers AF068829 and AF068830.
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